Remyelination therapy for demyelinating disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. CX3CL1/CX3CR1-dependent microglial phagocytosis of oligodendrocyte precursor cells contributes to sevoflurane-induced myelination impairments in neonatal mice.Journal of neuroinflammation · 2026
   Article
2. Automated analysis of gray matter damage in aged mice reveals impaired remyelination in the cuprizone model.Brain pathology (Zurich, Switzerland) · 2024
   Article
3. Hotair and Malat1 Long Noncoding RNAs Regulate Bdnf Expression and Oligodendrocyte Precursor Cell Differentiation.Molecular neurobiology · 2022
   Article
4. Oligodendroglial Epigenetics, from Lineage Specification to Activity-Dependent Myelination.Life (Basel, Switzerland) · 2021
   Review

Corrections and comments

• Comment on
  Inherited and acquired disorders of myelin: The underlying myelin pathology.2016
• Comment on
  Adulthood leukodystrophies.2018
• Comment on
  Leukodystrophies - much more than just diseases of myelin.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as